Co-Clinical Trial of Olaparib and Temozolomide in SCLC PDX Models

April 18, 2018
Benjamin J. Drapkin, MD, PhD

Benjamin J. Drapkin, MD, PhD, clinical fellow in medicine, Dana-Farber Cancer Institute, resident, Massachusetts General Hospital, discusses the co-clinical trial of olaparib (Lynparza) and temozolomide (temodar) in small cell lung cancer (SCLC) patient-derived xenografts (PDX) models during the 2018 AACR Annual Meeting.

Benjamin J. Drapkin, MD, PhD, clinical fellow in medicine, Dana-Farber Cancer Institute, resident, Massachusetts General Hospital, discusses the co-clinical trial of olaparib (Lynparza) and temozolomide (temodar) in small cell lung cancer (SCLC) patient-derived xenografts (PDX) models during the 2018 AACR Annual Meeting.

In an effort to uncover new biomarkers of sensitivity for SCLC, investigators generated PDX models from circulating tumor cells, biopsies, and malignant infusions. The activity of the combination of olaparib and temozolomide was then assessed in a panel of PDX models, responses of which was then compared with molecular profiles to identify candidate biomarkers.

These are early results, but the co-clinical has the potential to refine the clinical application of olaparib and temozolomide in real time, which may optimize clinical trials for SCLC in the future, Drapkin concludes.